CBGBench: Fill in the Blank of Protein-Molecule Complex Binding Graph
0
Sign in to get full access
Introduction
CBGBench is a benchmark dataset for evaluating the performance of machine learning models in predicting the binding affinity between proteins and small molecules. This task is crucial for structure-based drug design, where researchers aim to identify potential drug candidates by simulating the interactions between a target protein and a library of candidate molecules.
Background
CBGBench Dataset
The CBGBench dataset contains information about the binding interactions between proteins and small molecules, including the 3D structures of the protein-molecule complexes and the experimentally measured binding affinities. This dataset can be used to train and evaluate machine learning models that aim to predict the binding affinity between a given protein and a small molecule.
Structure-Based Drug Design Benchmark and Geometric Informed GFlowNets for Structure-Based Drug Design are related papers that also focus on structure-based drug design using machine learning.
Importance of Protein-Molecule Binding Prediction
Accurately predicting the binding affinity between a protein and a small molecule is crucial for structure-based drug design. This information can help researchers identify potential drug candidates, understand the mechanisms of drug action, and optimize the properties of drug molecules. By using machine learning models to make these predictions, researchers can streamline the drug discovery process and potentially accelerate the development of new therapies.
Technical Explanation
The CBGBench dataset consists of protein-molecule complex structures, where the goal is to predict the binding affinity between the protein and the small molecule. The dataset includes a set of 3D structures for the protein-molecule complexes, as well as the corresponding experimental binding affinity measurements.
The authors propose a benchmark task, called "Fill in the Blank", where the goal is to predict the binding affinity of a protein-molecule complex given the 3D structures of the protein, the molecule, and the complex, but with the binding affinity value missing. This task simulates a real-world drug discovery scenario, where researchers would have the structural information about a potential drug candidate and its target protein, but would need to predict the binding affinity to assess its drug-like properties.
The authors suggest that this benchmark can be used to evaluate the performance of various machine learning models, such as those based on Structure-Based Drug Design by Denoising Voxel, AutoDiff-AutoRegressive Diffusion Modeling for Structure-Based Drug Design, or Guided Multi-Objective Generative AI to Enhance approaches, in predicting the binding affinity of protein-molecule complexes.
Critical Analysis
The CBGBench dataset and the "Fill in the Blank" benchmark task provide a valuable resource for evaluating the performance of machine learning models in the context of structure-based drug design. The dataset's inclusion of experimentally measured binding affinities adds credibility to the benchmark, as it allows for a direct comparison between the model predictions and the ground truth.
However, the authors acknowledge that the dataset may be limited in its size and diversity, which could impact the generalization of the models trained on it. Additionally, the "Fill in the Blank" task may not capture the full complexity of real-world drug discovery, where researchers often need to consider factors beyond just binding affinity, such as drug-like properties, pharmacokinetics, and toxicity.
Researchers interested in using the CBGBench dataset should carefully consider these limitations and explore ways to supplement or extend the benchmark to better reflect the challenges and priorities of structure-based drug design.
Conclusion
The CBGBench dataset and the "Fill in the Blank" benchmark task provide a valuable resource for evaluating the performance of machine learning models in predicting the binding affinity between proteins and small molecules. This task is crucial for structure-based drug design, as accurate binding affinity prediction can help researchers identify potential drug candidates and optimize their properties.
While the dataset and benchmark have limitations, they represent an important step towards developing more reliable and efficient machine learning approaches for structure-based drug design. Researchers in this field can use the CBGBench benchmark to assess the capabilities of their models and identify areas for further improvement, ultimately contributing to the advancement of drug discovery and the development of new therapeutic interventions.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
CBGBench: Fill in the Blank of Protein-Molecule Complex Binding Graph
Haitao Lin, Guojiang Zhao, Odin Zhang, Yufei Huang, Lirong Wu, Zicheng Liu, Siyuan Li, Cheng Tan, Zhifeng Gao, Stan Z. Li
Structure-based drug design (SBDD) aims to generate potential drugs that can bind to a target protein and is greatly expedited by the aid of AI techniques in generative models. However, a lack of systematic understanding persists due to the diverse settings, complex implementation, difficult reproducibility, and task singularity. Firstly, the absence of standardization can lead to unfair comparisons and inconclusive insights. To address this dilemma, we propose CBGBench, a comprehensive benchmark for SBDD, that unifies the task as a generative heterogeneous graph completion, analogous to fill-in-the-blank of the 3D complex binding graph. By categorizing existing methods based on their attributes, CBGBench facilitates a modular and extensible framework that implements various cutting-edge methods. Secondly, a single task on textit{de novo} molecule generation can hardly reflect their capabilities. To broaden the scope, we have adapted these models to a range of tasks essential in drug design, which are considered sub-tasks within the graph fill-in-the-blank tasks. These tasks include the generative designation of textit{de novo} molecules, linkers, fragments, scaffolds, and sidechains, all conditioned on the structures of protein pockets. Our evaluations are conducted with fairness, encompassing comprehensive perspectives on interaction, chemical properties, geometry authenticity, and substructure validity. We further provide the pre-trained versions of the state-of-the-art models and deep insights with analysis from empirical studies. The codebase for CBGBench is publicly accessible at url{https://github.com/Edapinenut/CBGBench}.
Read more7/23/2024
0
General Binding Affinity Guidance for Diffusion Models in Structure-Based Drug Design
Yue Jian, Curtis Wu, Danny Reidenbach, Aditi S. Krishnapriyan
Structure-Based Drug Design (SBDD) focuses on generating valid ligands that strongly and specifically bind to a designated protein pocket. Several methods use machine learning for SBDD to generate these ligands in 3D space, conditioned on the structure of a desired protein pocket. Recently, diffusion models have shown success here by modeling the underlying distributions of atomic positions and types. While these methods are effective in considering the structural details of the protein pocket, they often fail to explicitly consider the binding affinity. Binding affinity characterizes how tightly the ligand binds to the protein pocket, and is measured by the change in free energy associated with the binding process. It is one of the most crucial metrics for benchmarking the effectiveness of the interaction between a ligand and protein pocket. To address this, we propose BADGER: Binding Affinity Diffusion Guidance with Enhanced Refinement. BADGER is a general guidance method to steer the diffusion sampling process towards improved protein-ligand binding, allowing us to adjust the distribution of the binding affinity between ligands and proteins. Our method is enabled by using a neural network (NN) to model the energy function, which is commonly approximated by AutoDock Vina (ADV). ADV's energy function is non-differentiable, and estimates the affinity based on the interactions between a ligand and target protein receptor. By using a NN as a differentiable energy function proxy, we utilize the gradient of our learned energy function as a guidance method on top of any trained diffusion model. We show that our method improves the binding affinity of generated ligands to their protein receptors by up to 60%, significantly surpassing previous machine learning methods. We also show that our guidance method is flexible and can be easily applied to other diffusion-based SBDD frameworks.
Read more6/26/2024
0
Structure-based Drug Design Benchmark: Do 3D Methods Really Dominate?
Kangyu Zheng, Yingzhou Lu, Zaixi Zhang, Zhongwei Wan, Yao Ma, Marinka Zitnik, Tianfan Fu
Currently, the field of structure-based drug design is dominated by three main types of algorithms: search-based algorithms, deep generative models, and reinforcement learning. While existing works have typically focused on comparing models within a single algorithmic category, cross-algorithm comparisons remain scarce. In this paper, to fill the gap, we establish a benchmark to evaluate the performance of sixteen models across these different algorithmic foundations by assessing the pharmaceutical properties of the generated molecules and their docking affinities with specified target proteins. We highlight the unique advantages of each algorithmic approach and offer recommendations for the design of future SBDD models. We emphasize that 1D/2D ligand-centric drug design methods can be used in SBDD by treating the docking function as a black-box oracle, which is typically neglected. The empirical results show that 1D/2D methods achieve competitive performance compared with 3D-based methods that use the 3D structure of the target protein explicitly. Also, AutoGrow4, a 2D molecular graph-based genetic algorithm, dominates SBDD in terms of optimization ability. The relevant code is available in https://github.com/zkysfls/2024-sbdd-benchmark.
Read more6/6/2024
0
What Ails Generative Structure-based Drug Design: Too Little or Too Much Expressivity?
Rafa{l} Karczewski, Samuel Kaski, Markus Heinonen, Vikas Garg
Several generative models with elaborate training and sampling procedures have been proposed recently to accelerate structure-based drug design (SBDD); however, perplexingly, their empirical performance turns out to be suboptimal. We seek to better understand this phenomenon from both theoretical and empirical perspectives. Since most of these models apply graph neural networks (GNNs), one may suspect that they inherit the representational limitations of GNNs. We analyze this aspect, establishing the first such results for protein-ligand complexes. A plausible counterview may attribute the underperformance of these models to their excessive parameterizations, inducing expressivity at the expense of generalization. We also investigate this possibility with a simple metric-aware approach that learns an economical surrogate for affinity to infer an unlabelled molecular graph and optimizes for labels conditioned on this graph and molecular properties. The resulting model achieves state-of-the-art results using 100x fewer trainable parameters and affords up to 1000x speedup. Collectively, our findings underscore the need to reassess and redirect the existing paradigm and efforts for SBDD.
Read more8/13/2024